LVTX — LAVA Therapeutics NV Share News
0.000.00%
Last trade - 00:00- $45.77m
- -$3.89m
- $11.98m
Brief: LAVA Doses First Patient In Phase 1 LAVA-1266 Study In Hematological Cancers
Lava Therapeutics Nv Reports Results For The Quarter Ended September 30: Earnings Summary
Lava Therapeutics Nv Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Lava Therapeutics Nv Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Lava Therapeutics Nv Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Lava Therapeutics Nv Expected To Post A Loss Of 33 Cents A Share: Earnings Preview
Lava Therapeutics Nv Reports Results For The Quarter Ended In June: Earnings Summary
Lava Therapeutics Nv Expected To Post A Loss Of 36 Cents A Share: Earnings Preview
Brief: Lava Provides Business Updates And Reports First Quarter 2024 Financial Results
Lava Therapeutics Nv Reports Results For The Quarter Ended In December: Earnings Summary
U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics
U.S. STOCKS ON THE MOVE-AeroVironment, Tesla, GitLab
U.S. STOCKS ON THE MOVE-Apogee Therapeutics ,Target, Enviva
LAVA Therapeutics rises after getting milestone payment from Pfizer
Brief: LAVA Announces Clinical Development Milestone Achieved By Pfizer For PF-08046052
U.S. STOCKS ON THE MOVE-Humana, Boeing, Tesla
U.S. STOCKS ON THE MOVE-ResMed, United Rentals, McCormick
U.S. STOCKS ON THE MOVE-Valero Energy, BlackBerry, Southwest Airlines
LAVA surges on Merck partnership for prostrate cancer treatment